letrozole has been researched along with Obesity in 29 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Women receiving adjuvant letrozole for T1-3N0-3M0 breast cancer with a body mass index (BMI) ≥ 24 kg/m(2) were eligible." | 9.19 | Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. ( Blackburn, GL; Findlay, B; Goodwin, PJ; Gralow, JR; Levine, M; Ligibel, JA; Mukherjee, S; Pond, GR; Pritchard, KI; Robidoux, A; Segal, RJ; Vallis, M, 2014) |
| "To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8." | 9.16 | Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. ( Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B, 2012) |
| " Metformin might represent a safe and promising adjuvant therapy to letrozole in overweight/obese postmenopausal women with breast cancer." | 8.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 8.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| " deltoidea at the dose of 500 and 1000 mg/kg/day reduced insulin resistance, obesity indices, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL), malondialdehyde (MDA), testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to near-normal levels in PCOS rats." | 8.02 | Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats. ( Goh, YM; Hashim, N; Haslan, MA; Samsulrizal, N; Shirazi, FH; Zin, NSNM, 2021) |
| "BACKGROUND The aim of this study was to explore whether letrozole and high-fat diets (HFD) can induce obese insulin-resistant polycystic ovary syndrome (PCOS) with all reproductive and metabolic phenotypes in a rat model." | 7.96 | Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways. ( Dun, J; Huang, L; Huang, M; Ji, F; Lin, Q; Lin, Y; Xu, J; Yang, J; You, X; Zhang, J, 2020) |
| " Polycystic ovary syndrome was induced by letrozole administration, and animals presented with obesity, sex hormone disorder, no ovulation, large cystic follicles, and increasing fasting insulin (FINS) and leptin levels." | 7.85 | Effects of Exercise Intervention on Preventing Letrozole-Exposed Rats From Polycystic Ovary Syndrome. ( Cao, SF; Hu, WL; Jiang, LY; Wu, MM, 2017) |
| "Isolated hypogonadotropic hypogonadism (IHH) is frequently observed in severely obese men, probably as a result of increased estradiol (E(2)) production and E(2)-mediated negative feedback on pituitary LH secretion." | 6.73 | Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. ( de Boer, H; Loves, S; Ruinemans-Koerts, J, 2008) |
| "We also investigated whether hyperinsulinemia occurs secondary to weight gain and insulin resistance in this model or if it can occur independently." | 5.46 | Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance. ( Anvar, AR; Hernández-Carretero, A; Rivera, AJ; Skarra, DV; Thackray, VG, 2017) |
| " Women receiving adjuvant letrozole for T1-3N0-3M0 breast cancer with a body mass index (BMI) ≥ 24 kg/m(2) were eligible." | 5.19 | Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. ( Blackburn, GL; Findlay, B; Goodwin, PJ; Gralow, JR; Levine, M; Ligibel, JA; Mukherjee, S; Pond, GR; Pritchard, KI; Robidoux, A; Segal, RJ; Vallis, M, 2014) |
| "To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8." | 5.16 | Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. ( Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B, 2012) |
| " The Pregnancy in PCOS trial II will determine the safety and efficacy of clomiphene citrate compared to letrozole, in achieving live birth in infertile women with PCOS." | 4.88 | Reproductive impact of polycystic ovary syndrome. ( Legro, RS; Usadi, RS, 2012) |
| " Metformin might represent a safe and promising adjuvant therapy to letrozole in overweight/obese postmenopausal women with breast cancer." | 4.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 4.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| " deltoidea at the dose of 500 and 1000 mg/kg/day reduced insulin resistance, obesity indices, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL), malondialdehyde (MDA), testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to near-normal levels in PCOS rats." | 4.02 | Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats. ( Goh, YM; Hashim, N; Haslan, MA; Samsulrizal, N; Shirazi, FH; Zin, NSNM, 2021) |
| "BACKGROUND The aim of this study was to explore whether letrozole and high-fat diets (HFD) can induce obese insulin-resistant polycystic ovary syndrome (PCOS) with all reproductive and metabolic phenotypes in a rat model." | 3.96 | Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways. ( Dun, J; Huang, L; Huang, M; Ji, F; Lin, Q; Lin, Y; Xu, J; Yang, J; You, X; Zhang, J, 2020) |
| "We conducted a secondary analysis of a multicenter, randomized clinical trial (Pregnancy in Polycystic Ovary Syndrome II, NCT00719186) comparing clomiphene citrate vs letrozole in the treatment of infertility." | 3.88 | Association among depression, symptom experience, and quality of life in polycystic ovary syndrome. ( Cedars, MI; Greenwood, EA; Huddleston, HG; Legro, RS; Pasch, LA, 2018) |
| " Polycystic ovary syndrome was induced by letrozole administration, and animals presented with obesity, sex hormone disorder, no ovulation, large cystic follicles, and increasing fasting insulin (FINS) and leptin levels." | 3.85 | Effects of Exercise Intervention on Preventing Letrozole-Exposed Rats From Polycystic Ovary Syndrome. ( Cao, SF; Hu, WL; Jiang, LY; Wu, MM, 2017) |
| "To compare occurrence of pregnancy among obese (body mass index [BMI] ≥30) and nonobese (BMI <30), infertile women undergoing ovulation induction with the aromatase inhibitor letrozole followed by intrauterine insemination (IUI)." | 3.77 | Body mass index-associated differences in response to ovulation induction with letrozole. ( Bates, GW; Chapman, VR; Cliver, SP; Cooper, JJ; McKnight, KK; Nodler, JL, 2011) |
| "Isolated hypogonadotropic hypogonadism (IHH) is frequently observed in severely obese men, probably as a result of increased estradiol (E(2)) production and E(2)-mediated negative feedback on pituitary LH secretion." | 2.73 | Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. ( de Boer, H; Loves, S; Ruinemans-Koerts, J, 2008) |
| "Letrozole is a highly effective nonsteroidal aromatase inhibitor that has been used to treat male subfertility in several case series with promising results." | 2.49 | Big enough for an aromatase inhibitor? How adiposity affects male fertility. ( Polotsky, AJ; Stephens, SM, 2013) |
| "tamoxifen." | 2.49 | Obesity and endocrine therapy: host factors and breast cancer outcome. ( Goodwin, PJ, 2013) |
| "Obesity is also a feature of this syndrome and contributes to associated metabolic abnormalities." | 2.48 | Polycystic ovarian syndrome management options. ( Bates, GW; Propst, AM, 2012) |
| "Polycystic ovarian syndrome is the major cause of anovulation and is generally associated with obesity." | 2.48 | Evaluation and treatment of anovulatory and unexplained infertility. ( Bates, GW; Propst, AM, 2012) |
| "Acne is an off-label use of some COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Letrozole (2." | 1.56 | Aromatase Inhibition Ameliorates Decreased LH Output Found in Obese Women. ( Bradford, AP; Carlson, NE; Chosich, J; Jones, K; Polotsky, AJ; Ryan, S; Santoro, N, 2020) |
| "This study aims to evaluate the effects and pregnancy outcomes of gonadotropin-releasing hormone agonist (GnRH agonist) combined with aromatase inhibitor (AI) in preserving the fertility of obese women with grade 1 endometrial cancer (EC)." | 1.51 | A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. ( Cheng, N; Feng, F; Huang, H; Wang, J; Zhang, Z, 2019) |
| "We also investigated whether hyperinsulinemia occurs secondary to weight gain and insulin resistance in this model or if it can occur independently." | 1.46 | Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance. ( Anvar, AR; Hernández-Carretero, A; Rivera, AJ; Skarra, DV; Thackray, VG, 2017) |
| "Obesity is a risk factor for breast cancer progression." | 1.42 | A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors. ( Goloubeva, O; McLenithan, J; Sabnis, G; Schech, A; Yu, S, 2015) |
| "Obesity is associated with an increased body aromatisation and may be a cause of insufficient estradiol depletion." | 1.39 | Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. ( Dressel-Ban, G; Dubsky, P; Exner, R; Fitzal, F; Gnant, M; Hadji, P; Königsberg, R; Maroske, M; Pfeiler, G; Seifert, M; Singer, C; Zellinger, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 19 (65.52) | 24.3611 |
| 2020's | 7 (24.14) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Y | 1 |
| Xiao, L | 1 |
| Li, S | 1 |
| Haslan, MA | 1 |
| Samsulrizal, N | 1 |
| Hashim, N | 1 |
| Zin, NSNM | 1 |
| Shirazi, FH | 1 |
| Goh, YM | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| El-Attar, AA | 1 |
| Ibrahim, OM | 1 |
| Alhassanin, SA | 1 |
| Essa, ES | 1 |
| Mostafa, TM | 1 |
| Rabah, HM | 1 |
| Mohamed, DA | 1 |
| Mariah, RA | 1 |
| Abd El-Khalik, SR | 1 |
| Khattab, HA | 1 |
| AbuoHashish, NA | 1 |
| Abdelsattar, AM | 1 |
| Raslan, MA | 1 |
| Farghal, EE | 1 |
| Eltokhy, AK | 1 |
| Jones, K | 1 |
| Ryan, S | 1 |
| Carlson, NE | 1 |
| Chosich, J | 1 |
| Bradford, AP | 1 |
| Santoro, N | 1 |
| Polotsky, AJ | 2 |
| Xu, J | 1 |
| Dun, J | 1 |
| Yang, J | 2 |
| Zhang, J | 4 |
| Lin, Q | 1 |
| Huang, M | 1 |
| Ji, F | 1 |
| Huang, L | 1 |
| You, X | 1 |
| Lin, Y | 1 |
| Skarra, DV | 1 |
| Hernández-Carretero, A | 1 |
| Rivera, AJ | 1 |
| Anvar, AR | 1 |
| Thackray, VG | 1 |
| Greenwood, EA | 1 |
| Pasch, LA | 1 |
| Cedars, MI | 1 |
| Legro, RS | 4 |
| Huddleston, HG | 1 |
| Winiczenko, R | 1 |
| Górnicki, K | 1 |
| Kaleta, A | 1 |
| Janaszek-Mańkowska, M | 1 |
| Khan, ZA | 1 |
| Singh, C | 1 |
| Khan, T | 1 |
| Ganguly, M | 1 |
| Bradsher, C | 1 |
| Goodwin, P | 1 |
| Petty, JT | 1 |
| Sandau, C | 1 |
| Bove, DG | 1 |
| Marsaa, K | 1 |
| Bekkelund, CS | 1 |
| Lindholm, MG | 1 |
| Salazar, J | 1 |
| Bermúdez, V | 1 |
| Olivar, LC | 1 |
| Torres, W | 1 |
| Palmar, J | 1 |
| Añez, R | 1 |
| Ordoñez, MG | 1 |
| Rivas, JR | 1 |
| Martínez, MS | 1 |
| Hernández, JD | 1 |
| Graterol, M | 1 |
| Rojas, J | 1 |
| Mubarak, Z | 1 |
| Humaira, A | 1 |
| Gani, BA | 1 |
| Muchlisin, ZA | 1 |
| Gremillet, C | 1 |
| Jakobsson, JG | 1 |
| Gomila, A | 1 |
| Shaw, E | 1 |
| Carratalà, J | 1 |
| Leibovici, L | 1 |
| Tebé, C | 1 |
| Wiegand, I | 1 |
| Vallejo-Torres, L | 1 |
| Vigo, JM | 1 |
| Morris, S | 1 |
| Stoddart, M | 1 |
| Grier, S | 1 |
| Vank, C | 1 |
| Cuperus, N | 1 |
| Van den Heuvel, L | 1 |
| Eliakim-Raz, N | 1 |
| Vuong, C | 1 |
| MacGowan, A | 1 |
| Addy, I | 1 |
| Pujol, M | 1 |
| Cobb, A | 1 |
| Rieger, E | 1 |
| Bell, J | 1 |
| Mallik, S | 1 |
| Zhao, Z | 1 |
| Szécsényi, Á | 1 |
| Li, G | 1 |
| Gascon, J | 1 |
| Pidko, EA | 1 |
| Zhang, GR | 1 |
| Wolker, T | 1 |
| Sandbeck, DJS | 1 |
| Munoz, M | 1 |
| Mayrhofer, KJJ | 1 |
| Cherevko, S | 1 |
| Etzold, BJM | 1 |
| Lukashuk, L | 1 |
| Yigit, N | 1 |
| Rameshan, R | 1 |
| Kolar, E | 1 |
| Teschner, D | 1 |
| Hävecker, M | 1 |
| Knop-Gericke, A | 1 |
| Schlögl, R | 1 |
| Föttinger, K | 1 |
| Rupprechter, G | 1 |
| Franconieri, F | 1 |
| Deshayes, S | 1 |
| de Boysson, H | 1 |
| Trad, S | 1 |
| Martin Silva, N | 1 |
| Terrier, B | 1 |
| Bienvenu, B | 1 |
| Galateau-Sallé, F | 1 |
| Emile, JF | 1 |
| Johnson, AC | 1 |
| Aouba, A | 1 |
| Vogt, TJ | 1 |
| Gevensleben, H | 1 |
| Dietrich, J | 1 |
| Kristiansen, G | 1 |
| Bootz, F | 1 |
| Landsberg, J | 1 |
| Goltz, D | 1 |
| Dietrich, D | 1 |
| Idorn, M | 1 |
| Skadborg, SK | 1 |
| Kellermann, L | 1 |
| Halldórsdóttir, HR | 1 |
| Holmen Olofsson, G | 1 |
| Met, Ö | 1 |
| Thor Straten, P | 1 |
| Johnson, LE | 1 |
| Brockstedt, D | 1 |
| Leong, M | 1 |
| Lauer, P | 1 |
| Theisen, E | 1 |
| Sauer, JD | 1 |
| McNeel, DG | 1 |
| Morandi, F | 1 |
| Marimpietri, D | 1 |
| Horenstein, AL | 1 |
| Bolzoni, M | 1 |
| Toscani, D | 1 |
| Costa, F | 1 |
| Castella, B | 1 |
| Faini, AC | 1 |
| Massaia, M | 1 |
| Pistoia, V | 1 |
| Giuliani, N | 1 |
| Malavasi, F | 1 |
| Qiu, J | 1 |
| Peng, S | 1 |
| Yang, A | 1 |
| Ma, Y | 1 |
| Han, L | 1 |
| Cheng, MA | 1 |
| Farmer, E | 1 |
| Hung, CF | 1 |
| Wu, TC | 1 |
| Modak, S | 1 |
| Le Luduec, JB | 1 |
| Cheung, IY | 1 |
| Goldman, DA | 1 |
| Ostrovnaya, I | 1 |
| Doubrovina, E | 1 |
| Basu, E | 1 |
| Kushner, BH | 1 |
| Kramer, K | 1 |
| Roberts, SS | 1 |
| O'Reilly, RJ | 1 |
| Cheung, NV | 1 |
| Hsu, KC | 1 |
| Salgarello, T | 1 |
| Giudiceandrea, A | 1 |
| Calandriello, L | 1 |
| Marangoni, D | 1 |
| Colotto, A | 1 |
| Caporossi, A | 1 |
| Falsini, B | 1 |
| Lefrançois, P | 1 |
| Xie, P | 1 |
| Wang, L | 2 |
| Tetzlaff, MT | 1 |
| Moreau, L | 1 |
| Watters, AK | 1 |
| Netchiporouk, E | 1 |
| Provost, N | 1 |
| Gilbert, M | 1 |
| Ni, X | 1 |
| Sasseville, D | 1 |
| Wheeler, DA | 1 |
| Duvic, M | 1 |
| Litvinov, IV | 1 |
| O'Connor, BJ | 1 |
| Fryda, NJ | 1 |
| Ranglack, DH | 1 |
| Yang, Y | 2 |
| Zhang, X | 2 |
| Grün, AL | 1 |
| Emmerling, C | 1 |
| Aumeeruddy-Elalfi, Z | 1 |
| Ismaël, IS | 1 |
| Hosenally, M | 1 |
| Zengin, G | 1 |
| Mahomoodally, MF | 1 |
| Dotsenko, A | 1 |
| Gusakov, A | 1 |
| Rozhkova, A | 1 |
| Sinitsyna, O | 1 |
| Shashkov, I | 1 |
| Sinitsyn, A | 1 |
| Hong, CE | 1 |
| Kim, JU | 1 |
| Lee, JW | 1 |
| Lee, SW | 1 |
| Jo, IH | 1 |
| Pandiyarajan, S | 1 |
| Premasudha, P | 1 |
| Kadirvelu, K | 1 |
| Wang, B | 1 |
| Luo, L | 1 |
| Wang, D | 1 |
| Ding, R | 1 |
| Hong, J | 1 |
| Caviezel, D | 1 |
| Maissen, S | 1 |
| Niess, JH | 1 |
| Kiss, C | 1 |
| Hruz, P | 1 |
| Pockes, S | 1 |
| Wifling, D | 1 |
| Keller, M | 1 |
| Buschauer, A | 1 |
| Elz, S | 1 |
| Santos, AF | 1 |
| Ferreira, IP | 1 |
| Pinheiro, CB | 1 |
| Santos, VG | 1 |
| Lopes, MTP | 1 |
| Teixeira, LR | 1 |
| Rocha, WR | 1 |
| Rodrigues, GLS | 1 |
| Beraldo, H | 1 |
| Lohar, S | 1 |
| Dhara, K | 1 |
| Roy, P | 1 |
| Sinha Babu, SP | 1 |
| Chattopadhyay, P | 1 |
| Sukwong, P | 1 |
| Sunwoo, IY | 1 |
| Lee, MJ | 1 |
| Ra, CH | 1 |
| Jeong, GT | 1 |
| Kim, SK | 2 |
| Huvinen, E | 1 |
| Eriksson, JG | 1 |
| Stach-Lempinen, B | 1 |
| Tiitinen, A | 1 |
| Koivusalo, SB | 1 |
| Malhotra, M | 1 |
| Suresh, S | 1 |
| Garg, A | 1 |
| Wei, L | 1 |
| Jiang, Y | 2 |
| Zhou, W | 1 |
| Liu, S | 1 |
| Liu, Y | 1 |
| Rausch-Fan, X | 1 |
| Liu, Z | 1 |
| Marques, WL | 1 |
| van der Woude, LN | 1 |
| Luttik, MAH | 1 |
| van den Broek, M | 1 |
| Nijenhuis, JM | 1 |
| Pronk, JT | 1 |
| van Maris, AJA | 1 |
| Mans, R | 1 |
| Gombert, AK | 1 |
| Xu, A | 1 |
| Sun, J | 1 |
| Li, J | 1 |
| Chen, W | 2 |
| Zheng, R | 1 |
| Han, Z | 1 |
| Ji, L | 1 |
| Shen, WQ | 1 |
| Bao, LP | 1 |
| Hu, SF | 1 |
| Gao, XJ | 1 |
| Xie, YP | 1 |
| Gao, XF | 1 |
| Huang, WH | 1 |
| Lu, X | 1 |
| Gostin, PF | 1 |
| Addison, O | 1 |
| Morrell, AP | 1 |
| Zhang, Y | 2 |
| Cook, AJMC | 1 |
| Liens, A | 1 |
| Stoica, M | 1 |
| Ignatyev, K | 1 |
| Street, SR | 1 |
| Wu, J | 1 |
| Chiu, YL | 1 |
| Davenport, AJ | 1 |
| Qiu, Z | 1 |
| Shu, J | 1 |
| Tang, D | 1 |
| Gao, X | 1 |
| Huang, K | 1 |
| Wai, H | 1 |
| Du, K | 1 |
| Anesini, J | 1 |
| Kim, WS | 1 |
| Eastman, A | 1 |
| Micalizio, GC | 1 |
| Liang, JH | 1 |
| Huo, XK | 1 |
| Cheng, ZB | 1 |
| Sun, CP | 1 |
| Zhao, JC | 1 |
| Kang, XH | 1 |
| Zhang, TY | 1 |
| Chen, ZJ | 1 |
| Yang, TM | 1 |
| Wu, YY | 1 |
| Deng, XP | 1 |
| Zhang, YX | 1 |
| Salem, HF | 1 |
| Kharshoum, RM | 1 |
| Abou-Taleb, HA | 1 |
| AbouTaleb, HA | 1 |
| AbouElhassan, KM | 1 |
| Ohata, C | 1 |
| Ohyama, B | 1 |
| Kuwahara, F | 1 |
| Katayama, E | 1 |
| Nakama, T | 1 |
| Kobayashi, S | 1 |
| Kashiwagi, T | 1 |
| Kimura, J | 1 |
| Lin, JD | 1 |
| Liou, MJ | 1 |
| Hsu, HL | 1 |
| Leong, KK | 1 |
| Chen, YT | 1 |
| Wang, YR | 1 |
| Hung, WS | 1 |
| Lee, HY | 1 |
| Tsai, HJ | 1 |
| Tseng, CP | 1 |
| Alten, B | 1 |
| Yesiltepe, M | 1 |
| Bayraktar, E | 1 |
| Tas, ST | 1 |
| Gocmen, AY | 1 |
| Kursungoz, C | 1 |
| Martinez, A | 1 |
| Sara, Y | 1 |
| Huang, S | 2 |
| Adams, E | 1 |
| Van Schepdael, A | 1 |
| Wang, Q | 1 |
| Chung, CY | 1 |
| Yang, W | 1 |
| Yang, G | 1 |
| Chough, S | 1 |
| Chen, Y | 1 |
| Yin, B | 1 |
| Bhattacharya, R | 1 |
| Hu, Y | 1 |
| Saeui, CT | 1 |
| Yarema, KJ | 1 |
| Betenbaugh, MJ | 1 |
| Zhang, H | 1 |
| Patik, JC | 1 |
| Tucker, WJ | 1 |
| Curtis, BM | 1 |
| Nelson, MD | 1 |
| Nasirian, A | 1 |
| Park, S | 1 |
| Brothers, RM | 1 |
| Dohlmann, TL | 1 |
| Hindsø, M | 1 |
| Dela, F | 1 |
| Helge, JW | 1 |
| Larsen, S | 1 |
| Gayani, B | 1 |
| Dilhari, A | 1 |
| Wijesinghe, GK | 1 |
| Kumarage, S | 1 |
| Abayaweera, G | 1 |
| Samarakoon, SR | 1 |
| Perera, IC | 1 |
| Kottegoda, N | 1 |
| Weerasekera, MM | 1 |
| Nardi, MV | 1 |
| Timpel, M | 1 |
| Ligorio, G | 1 |
| Zorn Morales, N | 1 |
| Chiappini, A | 1 |
| Toccoli, T | 1 |
| Verucchi, R | 1 |
| Ceccato, R | 1 |
| Pasquali, L | 1 |
| List-Kratochvil, EJW | 1 |
| Quaranta, A | 1 |
| Dirè, S | 1 |
| Heo, K | 1 |
| Jo, SH | 1 |
| Shim, J | 1 |
| Kang, DH | 1 |
| Kim, JH | 1 |
| Park, JH | 1 |
| Akhtar, N | 1 |
| Saha, A | 1 |
| Kumar, V | 1 |
| Pradhan, N | 1 |
| Panda, S | 1 |
| Morla, S | 1 |
| Kumar, S | 1 |
| Manna, D | 1 |
| Wang, H | 1 |
| Xu, E | 1 |
| Yu, S | 2 |
| Li, D | 1 |
| Quan, J | 1 |
| Xu, L | 1 |
| Saslow, SA | 1 |
| Um, W | 1 |
| Pearce, CI | 1 |
| Bowden, ME | 1 |
| Engelhard, MH | 1 |
| Lukens, WL | 1 |
| Kim, DS | 1 |
| Schweiger, MJ | 1 |
| Kruger, AA | 1 |
| Adair, LS | 1 |
| Kuzawa, C | 1 |
| McDade, T | 1 |
| Carba, DB | 1 |
| Borja, JB | 1 |
| Liang, X | 2 |
| Song, W | 1 |
| Wang, K | 1 |
| Zhang, B | 1 |
| Peele, ME | 1 |
| Luo, HR | 1 |
| Chen, ZY | 1 |
| Fei, JJ | 1 |
| Du, ZJ | 1 |
| Yi, KJ | 1 |
| Im, WT | 1 |
| Kim, DW | 1 |
| Ji, X | 1 |
| Zhang, C | 1 |
| Xu, Z | 1 |
| Ding, Y | 1 |
| Song, Q | 1 |
| Li, B | 2 |
| Zhao, H | 1 |
| Lee, DW | 1 |
| Lee, H | 1 |
| Kwon, BO | 1 |
| Khim, JS | 1 |
| Yim, UH | 1 |
| Park, H | 1 |
| Park, B | 1 |
| Choi, IG | 1 |
| Kim, BS | 1 |
| Kim, JJ | 1 |
| Wang, JJ | 1 |
| Chen, Q | 1 |
| Li, YZ | 1 |
| Sakai, M | 1 |
| Yamaguchi, M | 1 |
| Nagao, Y | 1 |
| Kawachi, N | 1 |
| Kikuchi, M | 1 |
| Torikai, K | 1 |
| Kamiya, T | 1 |
| Takeda, S | 1 |
| Watanabe, S | 1 |
| Takahashi, T | 1 |
| Arakawa, K | 1 |
| Nakano, T | 1 |
| Rufo, S | 1 |
| Continentino, MA | 1 |
| Nikolaou, V | 1 |
| Plass, F | 1 |
| Planchat, A | 1 |
| Charisiadis, A | 1 |
| Charalambidis, G | 1 |
| Angaridis, PA | 1 |
| Kahnt, A | 1 |
| Odobel, F | 1 |
| Coutsolelos, AG | 1 |
| Fuentes, I | 1 |
| García-Mendiola, T | 1 |
| Sato, S | 1 |
| Pita, M | 1 |
| Nakamura, H | 1 |
| Lorenzo, E | 1 |
| Teixidor, F | 1 |
| Marques, F | 1 |
| Viñas, C | 1 |
| Liu, F | 1 |
| Qi, P | 1 |
| Zhang, L | 1 |
| Rocha, AL | 1 |
| Oliveira, FR | 1 |
| Azevedo, RC | 1 |
| Silva, VA | 1 |
| Peres, TM | 1 |
| Candido, AL | 1 |
| Gomes, KB | 1 |
| Reis, FM | 1 |
| Zhang, Z | 1 |
| Huang, H | 1 |
| Feng, F | 1 |
| Wang, J | 1 |
| Cheng, N | 1 |
| Stephens, SM | 1 |
| Pfeiler, G | 1 |
| Königsberg, R | 1 |
| Hadji, P | 1 |
| Fitzal, F | 1 |
| Maroske, M | 1 |
| Dressel-Ban, G | 1 |
| Zellinger, J | 1 |
| Exner, R | 1 |
| Seifert, M | 1 |
| Singer, C | 1 |
| Gnant, M | 1 |
| Dubsky, P | 1 |
| Goodwin, PJ | 2 |
| Segal, RJ | 1 |
| Vallis, M | 1 |
| Ligibel, JA | 1 |
| Pond, GR | 1 |
| Robidoux, A | 1 |
| Blackburn, GL | 1 |
| Findlay, B | 1 |
| Gralow, JR | 1 |
| Mukherjee, S | 1 |
| Levine, M | 1 |
| Pritchard, KI | 1 |
| Spritzer, PM | 1 |
| Motta, AB | 1 |
| Sir-Petermann, T | 1 |
| Diamanti-Kandarakis, E | 1 |
| Schech, A | 1 |
| Goloubeva, O | 1 |
| McLenithan, J | 1 |
| Sabnis, G | 1 |
| Cao, SF | 1 |
| Hu, WL | 1 |
| Wu, MM | 1 |
| Jiang, LY | 1 |
| Balen, AH | 1 |
| Morley, LC | 1 |
| Misso, M | 1 |
| Franks, S | 1 |
| Wijeyaratne, CN | 1 |
| Stener-Victorin, E | 1 |
| Fauser, BC | 1 |
| Norman, RJ | 1 |
| Teede, H | 1 |
| McKnight, KK | 1 |
| Nodler, JL | 1 |
| Cooper, JJ | 1 |
| Chapman, VR | 1 |
| Cliver, SP | 1 |
| Bates, GW | 3 |
| Ewertz, M | 1 |
| Gray, KP | 1 |
| Regan, MM | 1 |
| Ejlertsen, B | 1 |
| Price, KN | 1 |
| Thürlimann, B | 1 |
| Bonnefoi, H | 1 |
| Forbes, JF | 1 |
| Paridaens, RJ | 1 |
| Rabaglio, M | 1 |
| Gelber, RD | 1 |
| Colleoni, M | 1 |
| Láng, I | 1 |
| Smith, IE | 1 |
| Coates, AS | 1 |
| Goldhirsch, A | 1 |
| Mouridsen, HT | 1 |
| Usadi, RS | 1 |
| Propst, AM | 2 |
| Loves, S | 1 |
| Ruinemans-Koerts, J | 1 |
| de Boer, H | 1 |
| Reed, MJ | 1 |
| Purohit, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 20 Week Double-Blind Randomized Trial of Clomiphene Citrate and Letrozole for the Treatment of Infertility in Women With Polycystic Ovary Syndrome[NCT00719186] | Phase 3 | 750 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome[NCT04867252] | Phase 2 | 88 participants (Actual) | Interventional | 2021-05-03 | Completed | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer[NCT00463489] | 338 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome[NCT03625531] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring. (NCT00719186)
Timeframe: as few as 5 months, up to 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: Clomiphene Citrate | 72 |
| Arm B: Letrozole | 103 |
(NCT00719186)
Timeframe: as few as 5 months, up to 16 months
| Intervention | ovulations (Number) |
|---|---|
| Arm A: Clomiphene Citrate | 331 |
| Arm B: Letrozole | 388 |
(NCT00719186)
Timeframe: as few as 5 months, up to 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: Clomiphene Citrate | 103 |
| Arm B: Letrozole | 154 |
(NCT00719186)
Timeframe: as few as 5 months, up to 16 months
| Intervention | events (Number) |
|---|---|
| Arm A: Clomiphene Citrate | 13 |
| Arm B: Letrozole | 22 |
(NCT00719186)
Timeframe: September 2008 - December 2011
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Neonatal jaundice | Neonatal respiratory distress syndrome | Neonatal hospitalization >3 days | Intrauterine growth restriction | Neonatal infectin | Minor birth defect | Other complication | Congenital anomaly | Neonatal death | |
| Arm A: Clomiphene Citrate | 17 | 2 | 4 | 1 | 2 | 0 | 4 | 1 | 2 |
| Arm B: Letrozole | 27 | 7 | 4 | 5 | 2 | 1 | 5 | 4 | 1 |
10 reviews available for letrozole and Obesity
| Article | Year |
|---|---|
Recent advances in the understanding and management of polycystic ovary syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Female; Humans; Insulin Resistance; Letrozole; Obesity; Polycystic | 2019 |
Big enough for an aromatase inhibitor? How adiposity affects male fertility.
Topics: Adiposity; Aromatase Inhibitors; Evidence-Based Medicine; Humans; Infertility, Male; Letrozole; Male | 2013 |
Obesity and endocrine therapy: host factors and breast cancer outcome.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2013 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Consensus; Female; Fertility Agents, Female; Fertiliz | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
Reproductive impact of polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Clomiphene; Female; Fertilization in Vitro; Humans; Infant, Newborn; Infertil | 2012 |
Polycystic ovarian syndrome management options.
Topics: Clomiphene; Contraceptives, Oral, Hormonal; Estrogen Antagonists; Exercise; Female; Humans; Infertil | 2012 |
Evaluation and treatment of anovulatory and unexplained infertility.
Topics: Anovulation; Clomiphene; Diet; Evidence-Based Medicine; Exercise; Female; Fertility Agents, Female; | 2012 |
Aromatase regulation and breast cancer.
Topics: 2-Methoxyestradiol; Adult; Animals; Aromatase; Aromatase Inhibitors; Aryl Hydrocarbon Hydroxylases; | 2001 |
4 trials available for letrozole and Obesity
| Article | Year |
|---|---|
Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp | 2018 |
Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Exercise; Female; Follow-Up Studies; Humans; Letrozole; Lif | 2014 |
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2012 |
Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism.
Topics: Adult; Aromatase Inhibitors; Estradiol; Humans; Hypogonadism; Letrozole; Male; Middle Aged; Nitriles | 2008 |
15 other studies available for letrozole and Obesity
| Article | Year |
|---|---|
Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Female; Hyperinsulinism; Hypoglycemic Agents; Insu | 2021 |
Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats.
Topics: Animals; Antioxidants; Blood Glucose; Corpus Luteum; Disease Models, Animal; Endometrium; Female; Fi | 2021 |
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Estradiol; Female; Humans; Insulin; Leptin; Letrozole; | 2023 |
Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.
Topics: Animals; Female; Humans; Insulin Resistance; Letrozole; Lipids; Metformin; Mitochondria; Nanoparticl | 2023 |
Aromatase Inhibition Ameliorates Decreased LH Output Found in Obese Women.
Topics: Adolescent; Adult; Aromatase Inhibitors; Female; Follicle Stimulating Hormone; Gonadotropin-Releasin | 2020 |
Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Estrous Cycle; Female; Insulin; Insuli | 2020 |
Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.
Topics: Animals; Eating; Energy Metabolism; Female; Glucose; Hyperandrogenism; Hyperinsulinism; Insulin Resi | 2017 |
Association among depression, symptom experience, and quality of life in polycystic ovary syndrome.
Topics: Adult; Aromatase Inhibitors; Case-Control Studies; Clomiphene; Depression; Female; Fertility Agents, | 2018 |
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
Topics: Administration, Oral; Adult; Aromatase Inhibitors; Birth Rate; Endometrial Neoplasms; Female; Fertil | 2019 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estra | 2013 |
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Blood Glucose; Cell | 2015 |
Effects of Exercise Intervention on Preventing Letrozole-Exposed Rats From Polycystic Ovary Syndrome.
Topics: Animals; Aromatase Inhibitors; Body Weight; Disease Models, Animal; Female; Follicle Stimulating Hor | 2017 |
Body mass index-associated differences in response to ovulation induction with letrozole.
Topics: Adult; Alabama; Aromatase Inhibitors; Body Mass Index; Chi-Square Distribution; Female; Fertility Ag | 2011 |
Top 10 health stories of 2003.
Topics: Aging; Angioplasty, Balloon, Coronary; Antineoplastic Agents; Breast Neoplasms; Dietary Carbohydrate | 2003 |